Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily

פריטים דומים

• Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
  מאת: Kantarjian, Hagop, et al.
  יצא לאור: (2009)
• Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily: Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)
  מאת: Kantarjian, Hagop, et al.
  יצא לאור: (2009)
• BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
  מאת: Hughes, T P, et al.
  יצא לאור: (2015)
• Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
  מאת: Hughes, Timothy P., et al.
  יצא לאור: (2014)
• Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
  מאת: Jabbour, Elias, et al.
  יצא לאור: (2014)